Amylyx Pharmaceuticals (AMLX) said Tuesday that the US Food and Drug Administration has lifted a clinical hold on a phase 1 clinical trial of AMX0114, an amyotrophic lateral sclerosis treatment candidate.
The company said it is now in the process of opening US sites for screening, enrollment and dosing with the lifting of the clinical hold.
Amylyx said the lifting of the clinical hold comes as it expects to start a phase 1 clinical trial in Canada that will assess the safety and biological activity of AMX0114, adding that it anticipates early group data from the study this year.
Shares were down 5.2% ahead of Tuesday's opening bell.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。